Category: Lemtrada

Alemtuzumab outcomes by age: Post hoc analysis from the randomized CARE-MS studies over 8 years

  Abstract Background: Alemtuzumab significantly improved clinical and MRI outcomes vs. subcutaneous interferon beta-1a (SC IFNB-1a) in the CARE-MS trials (NCT00530348, NCT00548405),…

Stuart Schlossman

LEMTRADA: Who is the Right Patient for this Multiple Sclerosis Drug?

vlog produced by Aaron Boster, MD Click HERE to Subscribe for the MS Beacon Newsletter Information Shared by: MSViewsandNews,  Visit our…

Stuart Schlossman

Relapsing MS Therapy, Lemtrada, Carries Rare But Serious Risk of Stroke and Artery Tears, FDA Warns

December 2, 2018 The U.S. Food and Drug Administration (FDA) has issued a safety alert, warning about a rare but life-threatening risk of…

Stuart Schlossman

Video: WHO IS THE RIGHT DOCTOR FOR LEMTRADA?

In my last video, I addressed “who is the right patient for Lemtrada?” In this video I answer “Who is…

Stuart Schlossman

Alemtuzumab-induced autoimmunity: getting closer to answers

Publish date: March 6, 2018 By  Damian McNamara    Clinical Neurology News EXPERT ANALYSIS FROM ACTRIMS FORUM 2018 SAN DIEGO –…

Stuart Schlossman

Long-term Lemtrada Treatment Benefits Demonstrated in Extension Study

October 2, 2017 A five-year study demonstrated that Sanofi-Genzyme’s Lemtrada(alemtuzumab) provides long-term benefits for relapsing-remitting multiple sclerosis patients, reducing relapse rates and preventing…

Stuart Schlossman

Relapsing-remitting MS: Alemtuzumab boosts outcomes for black patients

                                       …

Stuart Schlossman

Multiple Sclerosis Drug Could Reverse Physical Symptoms

                                       …

Stuart Schlossman

Lemtrada Offers Long-Term Stability in MS Patients

                                       …

Stuart Schlossman

ClinicSpeak & NeuroSpeak: sequencing DMTs switching from natalizumab to alemtuzumab

                                       …

Stuart Schlossman

Categories

Latest Blog Posts